Flagship-backed cancer biotech Ensemble quietly shuts down

During its 13-year existence, the Cambridge biotech made waves by announcing a series of partnership deals with large drugmakers. But it raised relatively little in equity financing and never launched a clinical trial.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news